Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan H Fox

Showing results (101-110 of 178) with videos related to

Pageof 18
Sort By:
Archives of Neurology|April 14, 2010
Serotonin 2A receptors and visual hallucinations in Parkinson diseaseBenedicte Ballanger, Antonio P Strafella, Thilo van Eimeren, et al.
Movement Disorders Clinical Practice|September 29, 2023
Amantadine-Induced Craniofacial Myoclonus: Distinctive Iatrogenic Dysarthria in Parkinson's DiseaseIris Lin, Laura Armengou-Garcia, Sanskriti Sasikumar, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 12, 2013
The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaquesJames B Koprich, Philippe Huot, Susan H Fox, et al.
Movement Disorders Clinical Practice|October 27, 2018
Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's DiseaseSean J Udow, Douglas E Hobson, Galit Kleiner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 18, 2019
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine reviewKlaus Seppi, K Ray Chaudhuri, Miguel Coelho, et al.
Parkinsonism & Related Disorders|August 21, 2012
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept studyTom H Johnston, Philippe Huot, Sammie Damude, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 9, 2006
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseNaomi P Visanji, Jordi Gomez-Ramirez, Tom H Johnston, et al.
The European Journal of Neuroscience|January 4, 2013
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaquePhilippe Huot, Tom H Johnston, Tessa Snoeren, et al.
Neuropharmacology|June 17, 2018
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's diseaseTom H Johnston, Alix M B Lacoste, Naomi P Visanji, et al.
NPJ Parkinson'S Disease|December 13, 2025
Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed casesSusan H Fox, Daniel G Luca, Ronald B Postuma, et al.
Pageof 18

Showing results (101-110 of 178) with videos related to

Sort By:
Pageof 18
Archives of Neurology|April 14, 2010
Serotonin 2A receptors and visual hallucinations in Parkinson diseaseBenedicte Ballanger, Antonio P Strafella, Thilo van Eimeren, et al.
Movement Disorders Clinical Practice|September 29, 2023
Amantadine-Induced Craniofacial Myoclonus: Distinctive Iatrogenic Dysarthria in Parkinson's DiseaseIris Lin, Laura Armengou-Garcia, Sanskriti Sasikumar, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 12, 2013
The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaquesJames B Koprich, Philippe Huot, Susan H Fox, et al.
Movement Disorders Clinical Practice|October 27, 2018
Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's DiseaseSean J Udow, Douglas E Hobson, Galit Kleiner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 18, 2019
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine reviewKlaus Seppi, K Ray Chaudhuri, Miguel Coelho, et al.
Parkinsonism & Related Disorders|August 21, 2012
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept studyTom H Johnston, Philippe Huot, Sammie Damude, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 9, 2006
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseNaomi P Visanji, Jordi Gomez-Ramirez, Tom H Johnston, et al.
The European Journal of Neuroscience|January 4, 2013
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaquePhilippe Huot, Tom H Johnston, Tessa Snoeren, et al.
Neuropharmacology|June 17, 2018
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's diseaseTom H Johnston, Alix M B Lacoste, Naomi P Visanji, et al.
NPJ Parkinson'S Disease|December 13, 2025
Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed casesSusan H Fox, Daniel G Luca, Ronald B Postuma, et al.
Pageof 18